[
    {
        "question": "A 21-year-old male presents to his primary care provider for fatigue. He reports that he graduated from college last month and returned 3 days ago from a 2 week vacation to Vietnam and Cambodia. For the past 2 days, he has developed a worsening headache, malaise, and pain in his hands and wrists. The patient has a past medical history of asthma managed with albuterol as needed. He is sexually active with both men and women, and he uses condoms \u201cmost of the time.\u201d On physical exam, the patient\u2019s temperature is 102.5\u00b0F (39.2\u00b0C), blood pressure is 112/66 mmHg, pulse is 105/min, respirations are 12/min, and oxygen saturation is 98% on room air. He has tenderness to palpation over his bilateral metacarpophalangeal joints and a maculopapular rash on his trunk and upper thighs. Tourniquet test is negative. Laboratory results are as follows:\n\nHemoglobin: 14 g/dL\nHematocrit: 44%\nLeukocyte count: 3,200/mm^3\nPlatelet count: 112,000/mm^3\n\nSerum:\nNa+: 142 mEq/L\nCl-: 104 mEq/L\nK+: 4.6 mEq/L\nHCO3-: 24 mEq/L\nBUN: 18 mg/dL\nGlucose: 87 mg/dL\nCreatinine: 0.9 mg/dL\nAST: 106 U/L\nALT: 112 U/L\nBilirubin (total): 0.8 mg/dL\nBilirubin (conjugated): 0.3 mg/dL\n\nWhich of the following is the most likely diagnosis in this patient? Options: (D) Hepatitis A (A) Chikungunya (C) Epstein-Barr virus (B) Dengue fever (E) Typhoid fever",
        "label": "A",
        "answer": "Chikungunya",
        "options": {
            "A": "Chikungunya",
            "B": "Dengue fever",
            "C": "Epstein-Barr virus",
            "D": "Hepatitis A",
            "E": "Typhoid fever"
        },
        "response": "### **Final Diagnosis: Dengue Fever (B)**\n\n#### **Comprehensive Rationale:**\n\nThis patient\u2019s clinical presentation, travel history, and laboratory findings are **most consistent with dengue fever**, though **chikungunya remains an important differential diagnosis**. Below is a **refined, evidence-based synthesis** of the key findings supporting dengue as the most likely diagnosis:\n\n---\n\n### **1. Travel History & Epidemiology**\n- The patient recently traveled to **Vietnam and Cambodia**, both **hyperendemic for dengue fever** (transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes).\n- While **chikungunya** is also present in these regions, **dengue is far more prevalent**, with **millions of cases annually** in Southeast Asia compared to chikungunya, which has **sporadic outbreaks**.\n- The **2-week travel duration** aligns with the **3\u201314 day incubation period** of dengue.\n\n---\n\n### **2. Clinical Presentation: Classic Dengue Features**\n#### **Key Symptoms:**\n- **Fever (102.5\u00b0F / 39.2\u00b0C)** with **headache and malaise** (\"breakbone fever\" is a hallmark of dengue).\n- **Arthralgia (pain in hands/wrists)**: While **chikungunya is known for severe, persistent joint pain**, dengue can also cause **mild to moderate arthralgia**, particularly in the **small joints (hands/wrists)**.\n- **Maculopapular rash (trunk/upper thighs)**: A **common feature of dengue**, typically appearing **after the fever peaks** (day 3\u20135 of illness). The rash is **less prominent in chikungunya** and often **absent in early stages**.\n- **Negative tourniquet test**: Rules out **dengue hemorrhagic fever (DHF)**, which would typically show **petechiae or a positive tourniquet test** due to capillary leakage. The patient\u2019s **mild thrombocytopenia (112,000/mm\u00b3)** and **absence of bleeding** suggest **non-severe dengue**.\n\n#### **Why Not Chikungunya?**\n- While **chikungunya** can cause **fever, arthralgia, and rash**, it is **less likely** in this case because:\n  - **Joint pain in chikungunya is typically more severe and debilitating** (often involving **large joints like knees/ankles** and persisting for **weeks to months**).\n  - **Thrombocytopenia is less common in chikungunya** (platelets are usually **normal or only mildly low**).\n  - **Rash in chikungunya is often less pronounced** and may appear **later in the illness**.\n\n---\n\n### **3. Laboratory Findings: Strongly Supportive of Dengue**\n| **Finding**               | **Dengue**                          | **Chikungunya**                     | **Other Diagnoses**               |\n|---------------------------|-------------------------------------|-------------------------------------|-----------------------------------|\n| **Leukopenia (3,200/mm\u00b3)** | **Classic** (lymphopenia common)    | Possible (but less pronounced)      | EBV: **Lymphocytosis**            |\n| **Thrombocytopenia (112,000/mm\u00b3)** | **Common** (often <100,000 in severe cases) | **Less common** (usually normal) | Hepatitis A: **Normal platelets** |\n| **Mild transaminitis (AST/ALT 106/112 U/L)** | **Common** (viral hepatitis-like effect) | Possible (but less common) | Hepatitis A: **Markedly elevated (>1000 U/L)** |\n| **Normal bilirubin (0.8 mg/dL)** | **Expected** (jaundice rare in dengue) | **Expected** | Hepatitis A: **Elevated bilirubin** |\n| **Negative tourniquet test** | **Rules out DHF** (but not uncomplicated dengue) | **Not applicable** | Typhoid: **Not relevant** |\n\n#### **Key Takeaways from Labs:**\n- **Leukopenia + thrombocytopenia** are **highly suggestive of dengue** (seen in **~80% of cases**).\n- **Mild transaminitis** is **common in dengue** (due to viral hepatitis-like effect) but **not severe enough for hepatitis A** (which would have **AST/ALT >1000 U/L** and **elevated bilirubin**).\n- **Normal hemoglobin/hematocrit** rules out **hemolytic processes** (e.g., malaria, which is not an option here).\n\n---\n\n### **4. Exclusion of Other Diagnoses**\n| **Diagnosis**       | **Why It\u2019s Unlikely**                                                                 |\n|---------------------|--------------------------------------------------------------------------------------|\n| **(A) Chikungunya** | Less likely due to **milder joint pain, thrombocytopenia, and rash timing**.         |\n| **(C) EBV**         | Typically causes **pharyngitis, lymphadenopathy, and atypical lymphocytosis** (not seen here). |\n| **(D) Hepatitis A** | Would present with **jaundice, markedly elevated AST/ALT (>1000 U/L), and hyperbilirubinemia**. |\n| **(E) Typhoid Fever** | Causes **high fever, abdominal pain, relative bradycardia, and leukopenia** but **not rash or arthralgia**. |\n\n---\n\n### **5. Next Steps for Confirmation**\nWhile **dengue is the most likely diagnosis**, **confirmatory testing** should be performed:\n- **Dengue serology (IgM/IgG)** or **NS1 antigen test** (positive in early infection).\n- **Chikungunya serology (IgM)** if clinical suspicion remains high.\n- **PCR testing** (if available) for **dengue or chikungunya** (most sensitive in first 5 days of illness).\n\n#### **Management:**\n- **Supportive care**: Hydration, **acetaminophen (avoid NSAIDs due to bleeding risk)**, and **monitoring for warning signs of severe dengue** (e.g., abdominal pain, persistent vomiting, mucosal bleeding, lethargy).\n- **Avoid aspirin/NSAIDs** (increases bleeding risk in dengue).\n- **Follow-up platelet counts** to monitor for **progression to DHF** (though unlikely in this case).\n\n---\n\n### **Conclusion**\nThe **combination of fever, arthralgia, rash, leukopenia, thrombocytopenia, and recent travel to a dengue-endemic region** makes **dengue fever (B) the most likely diagnosis**. While **chikungunya (A) remains a differential**, the **clinical and laboratory findings favor dengue**. **Hepatitis A, EBV, and typhoid fever are effectively ruled out** by the patient\u2019s presentation and lab results.\n\n**Final Answer: (B) Dengue fever** \u2705"
    },
    {
        "question": "A 56-year-old man with a history of hypertension presents to his physician with progressive fatigue and new onset muscle cramps. He has had no recent changes to his medication regimen, which includes hydrochlorothiazide, lisinopril, and amlodipine. His temperature is 98.0\u00b0F (36.7\u00b0C), blood pressure is 174/111 mmHg, pulse is 70/min, respirations are 12/min, and oxygen saturation is 98% on room air. The patient's cardiopulmonary and abdominal exams are unremarkable. Laboratory values are ordered as seen below.\n\nSerum:\nNa+: 138 mEq/L\nCl-: 100 mEq/L\nK+: 3.3 mEq/L\nHCO3-: 33 mEq/L\nBUN: 20 mg/dL\nGlucose: 129 mg/dL\n\nWhat is the most likely underlying etiology of this patient's hypertension? Options: (C) Cortisol excess (E) Increased peripheral vascular resistance (D) Impaired kidney perfusion (B) Catecholamine-secreting mass (A) Aldosterone excess",
        "label": "A",
        "answer": "Aldosterone excess",
        "options": {
            "A": "Aldosterone excess",
            "B": "Catecholamine-secreting mass",
            "C": "Cortisol excess",
            "D": "Impaired kidney perfusion",
            "E": "Increased peripheral vascular resistance"
        },
        "response": "### **Most Likely Underlying Etiology: (A) Aldosterone Excess (Primary Hyperaldosteronism)**\n\n#### **Comprehensive Analysis and Synthesis of Evidence**\n\nThis patient\u2019s presentation\u2014**resistant hypertension, hypokalemia, metabolic alkalosis, and symptoms of muscle cramps/fatigue**\u2014strongly suggests **primary hyperaldosteronism (Conn\u2019s syndrome)** as the underlying cause. Below is a detailed evaluation of the clinical and laboratory findings, along with a critical assessment of alternative diagnoses.\n\n---\n\n### **1. Key Findings Supporting Aldosterone Excess**\n#### **A. Hypokalemia (K\u207a = 3.3 mEq/L)**\n- **Mechanism:** Aldosterone promotes **renal potassium excretion** in exchange for sodium reabsorption, leading to **hypokalemia**.\n- **Clinical Relevance:**\n  - The patient\u2019s **muscle cramps and fatigue** are classic symptoms of **hypokalemia**.\n  - While **hydrochlorothiazide (HCTZ)** can cause hypokalemia, the **severity (K\u207a = 3.3 mEq/L)** is **disproportionate** to typical thiazide-induced hypokalemia, suggesting an **additional aldosterone-driven mechanism**.\n\n#### **B. Metabolic Alkalosis (HCO\u2083\u207b = 33 mEq/L, Cl\u207b = 100 mEq/L)**\n- **Mechanism:** Aldosterone stimulates **hydrogen ion (H\u207a) excretion** in the distal nephron, leading to **bicarbonate retention** and **metabolic alkalosis**.\n- **Supporting Evidence:**\n  - **Low chloride (Cl\u207b = 100 mEq/L)** suggests **contraction alkalosis** (due to **volume depletion** and **aldosterone-mediated sodium retention**).\n  - This **biochemical triad (hypokalemia + metabolic alkalosis + low chloride)** is **highly specific** for **mineralocorticoid excess**.\n\n#### **C. Resistant Hypertension (BP = 174/111 mmHg on 3 Medications)**\n- **Mechanism:** Aldosterone causes **sodium retention, volume expansion, and hypertension** via **mineralocorticoid receptor activation**.\n- **Clinical Relevance:**\n  - The patient\u2019s **persistent hypertension despite HCTZ, lisinopril, and amlodipine** suggests a **secondary cause** (e.g., **aldosterone excess**).\n  - **Primary hyperaldosteronism is the most common cause of secondary hypertension**, accounting for **5\u201310% of all hypertension cases**.\n\n#### **D. Absence of Other Secondary Hypertension Features**\n- **No signs of renal artery stenosis (D):**\n  - **Normal BUN (20 mg/dL)** and **no evidence of renal impairment** make **impaired kidney perfusion** unlikely.\n- **No signs of pheochromocytoma (B):**\n  - **No paroxysmal hypertension, headaches, palpitations, or diaphoresis** (classic for **catecholamine excess**).\n- **No signs of Cushing\u2019s syndrome (C):**\n  - **Mild hyperglycemia (129 mg/dL)** is **non-specific** and **not diagnostic** of cortisol excess.\n  - **No truncal obesity, striae, or proximal muscle weakness** (common in Cushing\u2019s).\n\n---\n\n### **2. Why Other Diagnoses Are Less Likely**\n| **Diagnosis**               | **Why It\u2019s Unlikely**                                                                 |\n|-----------------------------|--------------------------------------------------------------------------------------|\n| **(C) Cortisol Excess**     | - **No Cushingoid features** (moon facies, striae, central obesity).                 |\n|                             | - **Mild hyperglycemia (129 mg/dL)** is **non-specific** (could be stress/obesity).   |\n|                             | - **Metabolic alkalosis is less common** in Cushing\u2019s (more likely **hypernatremia**).|\n| **(E) Increased Peripheral Vascular Resistance** | - **This is a mechanism, not an etiology** (could be due to **aldosterone excess**).  |\n|                             | - **Does not explain hypokalemia or metabolic alkalosis**.                          |\n| **(D) Impaired Kidney Perfusion** | - **No elevated BUN/creatinine** (would expect **prerenal azotemia**).               |\n|                             | - **No evidence of renal artery stenosis** (e.g., abdominal bruit, flash pulmonary edema). |\n| **(B) Catecholamine-Secreting Mass** | - **No paroxysmal symptoms** (headaches, palpitations, diaphoresis).                 |\n|                             | - **Hypertension is sustained, not episodic**.                                       |\n\n---\n\n### **3. Next Steps in Diagnosis and Management**\n#### **A. Confirmatory Testing for Primary Hyperaldosteronism**\n1. **Plasma Aldosterone/Renin Ratio (ARR):**\n   - **Elevated aldosterone + suppressed renin** (ARR > 20\u201330 ng/dL per ng/mL/hr) is **diagnostic**.\n   - **Must correct hypokalemia first** (low K\u207a can suppress aldosterone).\n2. **Salt Loading Test (Oral or IV):**\n   - **Failure to suppress aldosterone** after salt loading confirms **autonomous aldosterone production**.\n3. **Adrenal Imaging (CT/MRI):**\n   - To identify **adrenal adenoma** (most common cause) vs. **bilateral adrenal hyperplasia**.\n\n#### **B. Management**\n- **Medical Therapy:**\n  - **Mineralocorticoid receptor antagonists (spironolactone, eplerenone)** to **block aldosterone effects**.\n  - **Potassium-sparing diuretics (amiloride, triamterene)** if spironolactone is not tolerated.\n- **Surgical Therapy:**\n  - **Adrenalectomy** for **unilateral adenoma** (curative in ~50% of cases).\n\n---\n\n### **4. Conclusion**\nThe **combination of resistant hypertension, hypokalemia, metabolic alkalosis, and low chloride** is **classic for primary hyperaldosteronism**. The **absence of features suggesting Cushing\u2019s, pheochromocytoma, or renal artery stenosis** further supports this diagnosis. **Further workup with plasma aldosterone/renin ratio and adrenal imaging is warranted** to confirm and guide treatment.\n\n**Final Answer: (A) Aldosterone excess (Primary Hyperaldosteronism).**"
    },
    {
        "question": "A 47-year-old woman seeks evaluation at your office because she has had postcoital vaginal bleeding for the past 8 months with occasional intermenstrual watery, blood-tinged vaginal discharge. Her family history is negative for malignancies and inherited disorders. She is the result of a pregnancy complicated by numerous miscarriages in the 1960s, for which her mother received diethylstilbestrol. During a pelvic examination, you notice a polypoid mass on the anterior wall of the vagina. The bimanual examination is negative for adnexal masses. You suspect the presence of carcinoma and, therefore, send tissue samples to pathology, which confirmed the presence of malignant cells. Which of the following is the most likely malignant tumor in this patient? Options: (D) Verrucous carcinoma (C) Botryoid sarcoma (E) Squamous cell carcinoma (SCC) (A) Clear cell adenocarcinoma (B) Melanoma",
        "label": "A",
        "answer": "Clear cell adenocarcinoma",
        "options": {
            "A": "Clear cell adenocarcinoma",
            "B": "Melanoma",
            "C": "Botryoid sarcoma",
            "D": "Verrucous carcinoma",
            "E": "Squamous cell carcinoma (SCC)"
        },
        "response": "### **Final Diagnosis: (A) Clear Cell Adenocarcinoma**\n\n#### **Comprehensive Rationale**\n\n1. **Diethylstilbestrol (DES) Exposure \u2013 A Defining Risk Factor**\n   - The patient\u2019s mother received **DES during pregnancy in the 1960s**, a synthetic estrogen prescribed to prevent miscarriages. DES exposure is **strongly and specifically associated with clear cell adenocarcinoma (CCA) of the vagina and cervix** in female offspring.\n   - **Epidemiological evidence** confirms that DES-exposed women have a **40-fold increased risk** of developing CCA compared to unexposed women. The latency period for DES-related CCA typically ranges from **15 to 30 years**, aligning with the patient\u2019s age (47).\n   - This is a **pathognomonic association**\u2014no other malignancy in the given options has such a well-documented link to DES exposure.\n\n2. **Clinical Presentation \u2013 Classic for CCA**\n   - **Postcoital bleeding and intermenstrual watery, blood-tinged discharge** are hallmark symptoms of vaginal or cervical malignancies, particularly when associated with a **visible lesion**.\n   - The **polypoid mass on the anterior vaginal wall** is highly characteristic of CCA, which often presents as a **friable, nodular, or polypoid growth** rather than a flat or ulcerated lesion.\n   - The **absence of adnexal masses** on bimanual examination further supports a **primary vaginal origin**, consistent with CCA.\n\n3. **Pathological Confirmation**\n   - The biopsy confirmed **malignant cells**, and the clinical context overwhelmingly favors CCA. Histologically, CCA is characterized by:\n     - **Clear cells with glycogen-rich cytoplasm** (hence the name).\n     - **Papillary or glandular architecture** (often seen on H&E staining).\n     - **Associated squamous metaplasia** (common in DES-exposed patients).\n\n4. **Exclusion of Other Malignancies**\n   - **(D) Verrucous carcinoma**:\n     - A **well-differentiated squamous cell carcinoma** with a **warty, exophytic appearance**, typically associated with **HPV infection** (not DES).\n     - More common in older women and not linked to DES exposure.\n   - **(C) Botryoid sarcoma**:\n     - A subtype of **embryonal rhabdomyosarcoma**, almost exclusively seen in **children and adolescents** (rarely in adults).\n     - Presents as a **grape-like mass** in the vagina, not typically polypoid, and unrelated to DES.\n   - **(E) Squamous cell carcinoma (SCC)**:\n     - The **most common vaginal malignancy** in the general population, but **not specifically linked to DES exposure**.\n     - More commonly associated with **HPV infection, chronic inflammation, or lichen sclerosus**.\n     - Typically presents in **older women** (peak incidence in the 60s\u201370s) and often as an **ulcerated or flat lesion** rather than a polypoid mass.\n   - **(B) Melanoma**:\n     - **Extremely rare** in the vagina (accounts for <3% of vaginal malignancies).\n     - **Not associated with DES exposure** and would typically present as a **pigmented lesion**, which is not described here.\n\n5. **Age Consideration**\n   - While CCA is most commonly diagnosed in **women aged 15\u201330** (due to DES exposure in utero), cases have been reported **up to age 50 or later**. The patient\u2019s age (47) is **still within the plausible range** for DES-related CCA, particularly given the **long latency period** of this malignancy.\n\n---\n\n### **Conclusion**\nGiven the **uniquely strong association with DES exposure**, the **classic clinical presentation**, and the **pathological confirmation of malignancy**, **clear cell adenocarcinoma (A)** is the **most likely diagnosis** in this patient. The other options are either **not linked to DES**, **inconsistent with the clinical presentation**, or **far less probable** based on the patient\u2019s age and history.\n\n**Final Answer: (A) Clear cell adenocarcinoma** \u2705"
    }
]